SPPI News and Press, Spectrum Pharmaceuticals Inc. From 07/22/19

Recent pre-clinical data supports development of poziotinib for osimertinib resistance, as well as atypical mutations. Three new cohorts are currently open to patient enrollment in the ZENITH20 trial: Cohort 5 (Expansion Study), Cohort 6 (EGFR osimertinib failures), and Cohort 7 (Atypi...

Spectrum Pharmaceuticals (NASDAQ: SPPI ) initiated with Buy rating and $18 (114% upside) price target at B. Riley FBR. More news on: Spectrum Pharmaceuticals, Inc., Immunic, Inc., Amneal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Do not take yearly results too seriously. Instead, focus on four or five-year averages. - Warren Buffett A notable investment theme is that a company rarely stays stagnant while growth tends to occur in spurts. This phenomenon is best illustrated in a young growth story like Spectrum Pha...

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the appointment of Elizabeth Czerepak to the Board of Directors. Ms. Czerepak will also serve as the chair of Spectrum’s audit committee. ...

Integrated efficacy and safety results in 643 patients were consistent with individual trial results (ADVANCE and RECOVER) The integrated data demonstrated that eflapegrastim provided an absolute risk reduction of severe neutropenia of 6.5% compared to pegfilgrastim in Cycle 1 S...

Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Jefferies 2019 Global Healthcare Conference being held in New York. The company presentation is on Wednesday, June 5, 2019, at 3...

Spectrum Pharmaceuticals (NASDAQ: SPPI ) announces the full enrollment of cohort 2 of ZENITH20 trial for previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations. More news on: Spectrum Pharmaceuticals, Inc., Healthcare stocks news, Read mo...

Enrollment of cohort 2 was completed six months ahead of schedule Cohort 2 had a target enrollment of 87 NSCLC patients with HER2 exon 20 insertion mutations Topline results from cohort 2 are expected in mid 2020 Topline results from cohort 1, which enrolled NSCLC patients with...

Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the 20th Annual B. Riley FBR Investor Conference being held in Beverly Hills, CA. The company presentation is on Thursday, May 23, 2...

Spectrum Pharmaceuticals, Inc. (SPPI) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Shiv Kapoor – Vice President-Strategic Planning and Investor Relations Joe Turgeon – Chief Executive Officer and President Kurt Gustafson – Chie...